Presenting the founders of igevia

Gerhard Feilmayr and Dominik Flener founded igevia in 2018. The two entrepreneurs have almost 50 years of experience in the healthcare sector combined and share a great passion for communication and innovation.

24 years ago Gerhard Feilmayr founded his own advertising agency in Linz, called “eigen)art” with a major focus on the health sector. Coming from “classical” advertising, Gerhard and his team have been working on digitalization in communication and changing customer requirements for the past few years. The topic “allergy” and “allergy vaccination” has occupied the agency for more than 20 years by now, because eigen)art is one of the leading agencies in the DACH area for one of the largest manufacturers within the range of the specific immunotherapy.

“After more than 20 years as a communications service provider for Europe’s most renowned vaccine manufacturer, it was only natural to develop a product that benefits the patients. With igevia, we are breaking new ground within the allergen diagnostics. And we still have a lot to do for our igevia customers,” says Gerhard Feilmayr.

Dominik Flener has led the HealthCareConsulting Group for 13 years, which develops and implements communication concepts between pharmaceutical companies and doctors, pharmacists and patients. During this time, Dominik and his team have had just over 1,000,000 discussions with doctors and pharmacists. igevia uses this experience to build up a competent medical community for our customers to accompany them with their allergy therapy.

„It’s nice to see how positively the medical community is responding to igevia. We see that what igevia offers can close a gap in patient care, especially in the area of general practitioners,“ says Dominik Flener.

Posted by Nicole Dopler on 7/2/2018

We are using cookies

We use cookies to improve your experience on our website. By using this website you agree to the use of cookies.

More information

We are using cookies

We use cookies to improve your experience on our website. By using this website you agree to the use of cookies. More information